Amwill Health Care Ltd
Incorporated in 2009, Amwill Health Care is in the wholesale trading of pharmaceutical products[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales and Marketing Team Size count ・Standalone data |
|
||
| Total Employees count ・Standalone data |
|||
| Hair Care Revenue Mix % of total revenue ・Standalone data |
|||
| Lip Care Revenue Mix % of total revenue ・Standalone data |
|||
| Personal Care & Hygiene Revenue Mix % of total revenue ・Standalone data |
|||
| Skin Care Revenue Mix % of total revenue ・Standalone data |
|||
| Total Number of Products (SKUs) count ・Standalone data |
|||
| Number of States Covered count ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
- Corporate Action-Board approves Dividend
- Disclosure Under Regulation 42 Of SEBI (LODR) Regulations, 2015
-
Approval Of Unaudited Financial Results Of The Company For The Half Year Ended September 30, 2026, For The Financial Year 2026-27.
- Board approved H1 FY27 results, declared ₹0.50 interim dividend, record date October 30, 2026.
-
Board Meeting Outcome for Board Meeting Outcome Of The Meeting Of The Board Held On October 23Rd, 2026.
- Board approved H1 FY27 unaudited results, ₹0.50 interim dividend, record date October 30, 2026.
-
Board Meeting Intimation for Approval And Take On Record Unaudited Financial Results Of The Company For The Half Year Ended September 30, 2026 (H1) Of Financial Year 2026-27 And Consider Declaration Of An Interim Dividend To The Equity Shareholders.
- Board meets October 23, 2026 to approve H1 FY27 unaudited results and consider interim dividend.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from web
-
Annual Report 2025
from bse
Business Overview:[1][2]
AHCL specializes in Dermatology, Trichology, and Cosmetology. It develops advanced skincare solutions using high-performance dermatological actives, natural ingredients, and specialized formulation technologies to deliver clinically visible results. Through strategic partnerships with contract manufacturers, distributors, and product development experts, the company maintains capabilities across formulation, packaging, and distribution, while its core operational activities are managed by trusted partners.
The company integrates advanced research, evidence-based formulation technologies, clinically validated ingredients to develop solutions that deliver real, visible results.